title: Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
abstract: To determine the synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel (PTX) against prostate carcinoma (PC) cells by isobolographic analysis. We demonstrated that DAC could significantly increase the susceptibility of PC cells to PTX, and confirmed the synergy of DAC and PTX. DAC enhanced the PTX induced up-regulation of caspase activity and antiproliferative effect, resulting in an increase of cells in subG1 and G2/M phases. In addition, the synergy was observed in both androgen-dependent and -independent PC cell lines. It suggested that combination chemotherapy with DAC and PTX might be a new strategy to improve the clinical response rate of PC.
authors.affiliation: Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
authors.forename: Donghao
authors.initials: D
authors.lastname: Shang
authors.forename: Yuting
authors.initials: Y
authors.lastname: Liu
authors.forename: Qingjun
authors.initials: Q
authors.lastname: Liu
authors.forename: Fengbo
authors.initials: F
authors.lastname: Zhang
authors.forename: Lang
authors.initials: L
authors.lastname: Feng
authors.forename: Wencheng
authors.initials: W
authors.lastname: Lv
authors.forename: Ye
authors.initials: Y
authors.lastname: Tian
mesh_terms: D000728:Androgens / Q000502:physiology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D000077209:Decitabine; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008928:Mitochondria / Q000201:enzymology; D010088:Oxidoreductases / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D013778:Tetrazolium Salts / Q000378:metabolism; D015854:Up-Regulation
chemical_list: C110656:2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium; D000728:Androgens; D000972:Antineoplastic Agents, Phytogenic; D013778:Tetrazolium Salts; D000077209:Decitabine; D010088:Oxidoreductases; D020169:Caspases; D001374:Azacitidine; D017239:Paclitaxel